Your session is about to expire
← Back to Search
SBRT for Liver Metastases
Study Summary
This trial is testing a new type of radiation therapy that is noninvasive and uses MRI to help guide the therapy. The goal is to find the maximum tolerated dose level for this new type of radiation therapy.
- Liver Metastases
- Stereotactic Body Radiation Therapy
- Magnetic Resonance Imaging-guided Treatment
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2024 Phase 2 trial • 57 Patients • NCT03004183Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
What are the potential hazards of undergoing stereotactic body radiotherapy?
"The safety of SBRT has been deemend a 1 on our team's scale, as this study is in its first phase. This implies that the evidence for both efficacy and safety are limited."
Are there any open spots available for individuals to join this trial?
"Affirmative. Per the data posted on clinicaltrials.gov, this medical investigation is actively recruiting patients from one site and requires 48 participants in total. The trial was first published on November 4th 2019 and most recently updated on September 13th 2022."
What is the upper limit of participants involved in this clinical trial?
"Absolutely. Based on the information available via clinicaltrials.gov, this medical study is currently looking for 48 participants from a single site. This trial was initially posted on November 4th 2019 and has been updated most recently on September 13th 2022."
Share this study with friends
Copy Link
Messenger